NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Sidney Kimmel Comprehensive Cancer Center · University of Washington · +50 more institutions
Abstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared…
Citation impact
- FWCI
- 72.40
- Percentile
- 100%
- References
- 381
Authors
36- DSDavid S. EttingerCorresponding
Sidney Kimmel Comprehensive Cancer Center
- DEDouglas E. Wood
University of Washington, Seattle Cancer Care Alliance
- WAWallace Akerley
University of Utah, Huntsman Cancer Institute
- LBLyudmila Bazhenova
Moores Cancer Center, UC San Diego Health System
- HBHossein Borghaei
Fox Chase Cancer Center
Topics & keywords
- Medicine
- Lung cancer
- Oncology
- Intensive care medicine
- Good health and well-being